
First allogeneic cancer immunotherapy hits market
On December 20th, the European Commission approved Tabelecleucel (EbvalloTM) as a monotherapy for the treatment of adult and paediatric patients who...

Rewind Therapeutics extends Series A financing
The company, founded by CD3 (Leuven, Belgium) and Axxam S.p.A. (Milan), did not want to reveal the exact amount added to the €15.2m in its 2018...

Memo Therapeutics and Ono Pharmaceutical enter partnership
Under the terms of the agreement, Memo Therapeutics AG will leverage its microfluidic single-cell molecular cloning and screening technologies to...

BioNTech and Ryvu Therapeutics enter into global collaboration
BioNTech SE and Ryvu Therapeutics S.A. announced that the companies have entered into a multi-target research collaboration targeting immune...

Evonetix extends Series B financing to US$54m
According to Evonetix Ltd, a benchtop gene synthesis specialist, the investment, which also includes existing investors such as Molten Ventures,...

EpiEndo Pharmaceuticals pushes COPD candidate
The Icelandic inflammation specialist received regulatory approval for its Phase IIa trial of Barriolide™ (EP395) in patients with Chronic...

Amsterdam Neogene Therapeutics aquired by AstraZeneca
Neogene Therapeutics is developing both patient-specific and shared neoantigen TCR programmes to deliver such TCRs into a patient's own T cells and...